Shares of Hindustan Unilever (HUL) rise by more than 3% after brokerages respond to the company’s quarterly performance. Several brokerages reassess expectations following HUL’s June-quarter (Q1) results, with some firms cutting their target prices after reviewing earnings. Despite the target cuts, analysts keep a positive outlook, citing continued demand, HUL’s strategy of “premiumisation,” and the company’s ability to maintain margins. The mixed broker response reflects a split between near-term valuation adjustments and longer-term confidence in underlying business trends. Investors appear to react more to the retained bullish themes than to the revised price targets. Overall, the movement in HUL’s stock indicates that brokerages are adjusting forecasts after the quarterly miss, while still viewing growth drivers such as premium product mix and margin resilience as supportive for the company’s performance going ahead.
HUL shares rise over 3% after brokerages retain bullish stance despite Q1 miss
Shares of Hindustan Unilever (HUL) rise by more than 3% after brokerages respond to the company’s quarterly performance. Several brokerages reassess expectations following HUL’s June-quarter (Q1) resu...
- Hindustan Unilever (HUL) shares rise by more than 3%.
- Some brokerages cut their target prices following HUL’s June-quarter results.
- Despite the Q1 miss, analysts remain broadly positive on HUL’s outlook.
- Analysts cite factors including demand, premiumisation, and margin resilience.
- The stock reaction reflects market focus on growth themes even as price targets are revised.
Goldman Sachs and Citi cut target prices after June-quarter earnings, but analysts remained positive on demand, premiumisation and margin resilience.
19 hours agoGoldman Sachs and Citi cut target prices after June-quarter earnings, but analysts remained positive on demand, premiumisation and margin resilience.
19 hours ago
Fed holds interest rates steady as Iran tensions lift energy-price inflation risks
The U.S. Federal Reserve holds its benchmark interest rate steady for a fifth consecutive meeting on Wednesday, citing i...
Goldman-Backed Attovia Therapeutics Seeks up to $212.5 Million in US IPO
Attovia Therapeutics Inc., an early-stage biopharmaceutical company focused on immune-mediated diseases with significant...
Oil falls and stocks rise after US-Iran ceasefire framework hopes
Global markets react to shifting US-Iran diplomacy as traders weigh prospects for reduced conflict and the status of shi...